BAM
SEEL

Belpointe Asset Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Belpointe Asset Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13
Closed -$34.6K – 3545
2023
Q1 		$34.6K Hold
13
– – ﹤0.01% 1952
2022
Q4 		$34K Buy
+13
New +$45.3K ﹤0.01% 1838

Other funds holding SEEL

GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Belpointe Asset Management's SEEL Position: Q2 2023 in Review

Belpointe Asset Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2023, closing a stake of 13 shares — an estimated $34.6K sold.

Belpointe Asset Management first reported a position in SEEL in Q4 2022 and held it in 2 quarters. The position peaked at $34.6K in Q1 2023. 68 funds tracked by Wall St. Rank hold SEEL as of Q2 2023.

  • Belpointe Asset Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 13 Seelos Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $34.6K.
  • Belpointe Asset Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Seelos Therapeutics, Inc. Common Stock position peaked at $34.6K in Q1 2023.
  • 68 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.